Levocetirizine
| Clinical data | |
|---|---|
| Trade names | Xyzal, Levazyr, others |
| Other names | Levocetirizine dihydrochloride |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607056 |
| License data | |
| Routes of administration | By mouth |
| Drug class | Second generation antihistamines |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | High |
| Protein binding | 91–92% |
| Metabolism | Minimal (less than 14%, primarily CYP3A4) |
| Elimination half-life | 8 to 9 hours |
| Excretion | Urine: 85% Feces: 12.9% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H25ClN2O3 |
| Molar mass | 388.89 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Levocetirizine, sold under the brand name Xyzal, among others, is a second-generation antihistamine used for the treatment of allergic rhinitis (hay fever) and long-term hives of unclear cause. It is less sedating than older antihistamines. It is taken by mouth.
Common side effects include sleepiness, dry mouth, cough, vomiting, and diarrhea. Use in pregnancy appears safe but has not been well studied and use when breastfeeding is of unclear safety. It is classified as a second-generation antihistamine and works by blocking histamine H1-receptors.
Levocetirizine was approved for medical use in the United States in 2007, and is available as a generic medication. In 2022, it was the 152nd most commonly prescribed medication in the United States, with more than 3 million prescriptions.